Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

Expert Opinion on Biological Therapy

Volumn 16, Issue 10, 2016, Pages 1277-1290

  Pouillon, Lieven ^a   Bossuyt, Peter ^b   Peyrin Biroulet, Laurent ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b IMELDA HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Adalimumab; anti TNF; biosimilar; certolizumab pegol; combination therapy; Crohn s disease; golimumab; inflammatory bowel disease; infliximab; personalized medicine; pharmacogenomics; tailored therapy; therapeutic drug monitoring; TNF antagonists; ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIMETABOLITE; AZATHIOPRINE; BIOLOGICAL MARKER; BIOSIMILAR AGENT; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL (TOPIC); COST; CROHN DISEASE; DRUG CONTRAINDICATION; DRUG DOSE INTENSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; RECURRENCE RISK; REMISSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; PROCEDURES; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DRUG MONITORING; FORECASTING; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84985911667     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1203897     Document Type: Review

References (146)

1. D.C.Baumgart, W.J.Sandborn Crohn’s disease. Lancet. 2012;380:1590–1605. doi:10.1016/S0140-6736(12)60026-9.
2. I.Ordás, L.Eckmann, M.Talamini, et al. Ulcerative colitis. Lancet. 2012;380:1606–1619. doi:10.1016/S0140-6736(12)60150-0.
3. L.Peyrin-Biroulet, P.Desreumaux, W.J.Sandborn, et al. Crohn’s disease:beyond antagonists of tumour necrosis factor. Lancet. 2008;372:67–81. doi:10.1016/S0140-6736(08)60995-2.
4. B.Derkx, J.Taminiau, S.Radema, et al. Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet. 1993;342:173–174. doi:10.1016/0140-6736(93)91375-V.• Landmark case report of the first CD patient treated with anti-TNF.
5. H.M.van Dullemen, S.J.van Deventer, D.W.Hommes, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135. doi:10.1016/0016-5085(95)90277-5.
6. S.Singh, S.K.Garg, D.S.Pardi, et al. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease:a systematic review and network meta-analysis. Mayo Clin Proc. 2014;89:1621–1635. doi:10.1016/j.mayocp.2014.08.019.
7. R.W.Stidham, T.C.H.Lee, P.D.R.Higgins, et al. Systematic review with network meta-analysis:the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–1362. doi:10.1111/apt.12749.
8. G.S.Hazlewood, A.Rezaie, M.Borman, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease:a network meta-analysis. Gastroenterology. 2015;148:344–54.e5;quiz e14–5. doi:10.1053/j.gastro.2014.10.011.
9. S.Danese, G.Fiorino, L.Peyrin-Biroulet, et al. Biological agents for moderately to severely active ulcerative colitis:a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704–711. doi:10.7326/M13-2403.
10. R.W.Stidham, T.C.H.Lee, P.D.R.Higgins, et al. Systematic review with network meta-analysis:the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660–671. doi:10.1111/apt.12644.
11. L.Peyrin-Biroulet, A.Bressenot, W.Kampman. Histologic remission:the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929–34.e2. doi:10.1016/j.cgh.2013.07.022.
12. G.Pineton de Chambrun, P.Blanc, L.Peyrin-Biroulet. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2016;1–13. doi:10.1586/17474124.2016.1174064. Epub 2016 Apr18.
13. L.Peyrin-Biroulet, G.Fiorino, A.Buisson, et al. First-line therapy in adult Crohn’s disease:who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10:345–351. doi:10.1038/nrgastro.2013.31.
14. K.Papamichael, G.J.Mantzaris, L.Peyrin-Biroulet. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opin Drug Saf. 2016;15:493–501.
15. M.Rinaudo-Gaujous, S.Paul, E.D.Tedesco, et al. Review article:biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther. 2013;38:914–924. doi:10.1111/apt.12477.
16. S.Danese, L.Vuitton, L.Peyrin-Biroulet. Biologic agents for IBD:practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545. doi:10.1038/nrgastro.2015.135.
17. L.Peyrin-Biroulet, V.Billioud, G.D’Haens, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials:results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776. doi:10.1038/ajg.2012.117.
18. P.Lionetti, F.Bronzini, C.Salvestrini, et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2003;18:425–431. doi:10.1046/j.1365-2036.2003.01672.x.
19. S.Schreiber, J.-F.Colombel, R.Bloomfield, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol:an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574–1582. doi:10.1038/ajg.2010.78.
20. S.Schreiber, W.Reinisch, J.F.Colombel, et al. Subgroup analysis of the placebo-controlled CHARM trial:increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7:213–221. doi:10.1016/j.crohns.2012.10.011.
21. G.D’Haens, F.Baert, G.van Assche, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease:an open randomised trial. Lancet. 2008;371:660–667. doi:10.1016/S0140-6736(08)60304-9.•• Landmark trial proving the concept of a top-down approach with anti-TNF therapy in CD.
22. R.Khanna, B.Bressler, B.G.Levesque, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT):a cluster randomised controlled trial. Lancet. 2015;386:1825–1834. doi:10.1016/S0140-6736(15)00068-9.•• REACT trial:first cluster randomized controlled trial designed to address concerns regarding the safety and efficacy of early combined immunosuppression in community practices in patients with long-established CD.
23. V.Nuij, G.M.Fuhler, A.J.Edel, et al. Benefit of earlier anti-TNF treatment on IBD disease complications? J Crohns Colitis. 2015;9:997–1003. doi:10.1093/ecco-jcc/jjv130.
24. E.Safroneeva, S.R.Vavricka, N.Fournier, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:977–989. doi:10.1111/apt.13365.
25. A.Dignass, J.O.Lindsay, A.Sturm, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2:current management. J Crohns Colitis. 2012;6:991–1030. doi:10.1016/j.crohns.2012.09.002.
26. G.R.D’Haens, R.Panaccione, P.D.R.Higgins, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization:when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212;quiz 213. doi:10.1038/ajg.2010.392.
27. A.Dignass, G.Van Assche, J.O.Lindsay, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease:current management. J Crohns Colitis. 2010;4:28–62. doi:10.1016/j.crohns.2009.12.002.
28. D.H.Present, P.Rutgeerts, S.Targan, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405. doi:10.1056/NEJM199905133401909.
29. B.E.Sands, F.H.Anderson, C.N.Bernstein, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885. doi:10.1056/NEJMoa030815.
30. J.-F.Colombel, D.A.Schwartz, W.J.Sandborn, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–948. doi:10.1136/gut.2008.159251.
31. P.Dewint, B.E.Hansen, E.Verhey, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease:a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292–299. doi:10.1136/gutjnl-2013-304488.
32. C.J.van der Woude, S.Ardizzone, M.B.Bengtson, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124. doi:10.1093/ecco-jcc/jju006.
33. Z.Zelinkova, C.de Haar, L.de Ridder, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053–1058. doi:10.1111/j.1365-2036.2011.04617.x.
34. M.Julsgaard, L.A.Christensen, P.R.Gibson, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016. doi:10.1053/j.gastro.2016.04.002.
35. O.M.Damas, A.R.Deshpande, D.J.Avalos, et al. Treating inflammatory bowel disease in pregnancy:the issues we face today. J Crohns Colitis. 2015;9:928–936. doi:10.1093/ecco-jcc/jjv118.
36. S.R.Vavricka, N.Bentele, M.Scharl, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18:1523–1530. doi:10.1002/ibd.21888.
37. E.S.Kim, K.O.Kim, B.I.Jang, et al. Factors contributing to the preference of Korean patients with Crohn’s disease when selecting an anti-tumor necrosis factor agent (CHOICE study). Gut Liver. 2016;10:391–398.
38. A.Lopez, V.Billioud, C.Peyrin-Biroulet, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases:a systematic review. Inflamm Bowel Dis. 2013;19:1528–1533. doi:10.1097/MIB.0b013e31828c8512.
39. H.H.Fidder, M.M.J.Singendonk, M.van der Have, et al. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis:results of a systematic review. World J Gastroenterol. 2013;19:4344–4350. doi:10.3748/wjg.v19.i27.4344.
40. G.Van Assche, S.Vermeire, V.Ballet, et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab:prospective randomised SWITCH trial. Gut. 2012;61:229–234. doi:10.1136/gutjnl-2011-300755.•• SWITCH trial:randomized controlled trial on elective switching from infliximab to adalimumab in CD patients in stable remission.
41. F.Hoentjen, B.J.T.Haarhuis, J.P.H.Drenth, et al. Elective switching from infliximab to adalimumab in stable Crohn’s disease. Inflamm Bowel Dis. 2013;19:761–766. doi:10.1097/MIB.0b013e3182802ae1.
42. M.Bhalme, A.Sharma, R.Keld, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol. 2013;25:543–549. doi:10.1097/MEG.0b013e32835d1f15.
43. J.P.Gisbert, J.Panés. Loss of response and requirement of infliximab dose intensification in Crohn’s disease:a review. Am J Gastroenterol. 2009;104:760–767. doi:10.1038/ajg.2008.88.
44. V.Billioud, W.J.Sandborn, L.Peyrin-Biroulet. Loss of response and need for adalimumab dose intensification in Crohn’s disease:a systematic review. Am J Gastroenterol. 2011;106:674–684. doi:10.1038/ajg.2011.60.
45. J.F.Colombel, W.J.Sandborn, W.Reinisch, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395. doi:10.1056/NEJMoa0904492.•• SONIC trial:clinical trial demonstrating the synergistic efficacy of immunomodulation and anti-TNF therapy in CD.
46. R.Panaccione, S.Ghosh, S.Middleton, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.e3. doi:10.1053/j.gastro.2013.10.052.•• UC SUCCESS trial:clinical trial demonstrating the synergistic efficacy of immunomodulation and anti-TNF therapy in UC.
47. B.G.Feagan, J.W.D.McDonald, R.Panaccione, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681–8.e1. doi:10.1053/j.gastro.2013.11.024.
48. N.Narula, L.Peyrin-Biroulet, J.-F.Colombel. Combination therapy with methotrexate in inflammatory bowel disease:time to COMMIT? Gastroenterology. 2014;146:608–611. doi:10.1053/j.gastro.2014.01.040.
49. J.L.Jones, G.G.Kaplan, L.Peyrin-Biroulet, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease:a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13:2233–40.e2. doi:10.1016/j.cgh.2015.06.034.
50. T.Matsumoto, S.Motoya, K.Watanabe, et al. Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease:a prospective, multicentre, open-labelled clinical trial (DIAMOND study). J Crohns Colitis. 2016;10:S8.
51. M.T.Osterman, K.Haynes, E.Delzell, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1293–301.e5;quiz e70, e72. doi:10.1016/j.cgh.2015.02.017.
52. L.Peyrin-Biroulet, J.Salleron, J.Filippi, et al. Anti-TNF monotherapy for Crohn’s disease:a 13-year multicentre experience. J Crohns Colitis. 2016. Epub 2016 Jan22. doi:10.1093/ecco-jcc/jjw008.
53. N.S.Ding, A.Hart, P.De Cruz. Systematic review:predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30–51. doi:10.1111/apt.2016.43.issue-1.
54. T.Billiet, P.Rutgeerts, M.Ferrante, et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14:75–101. doi:10.1517/14712598.2014.858695.
55. D.J.Gibson, Z.S.Heetun, C.E.Redmond, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–5.e1. doi:10.1016/j.cgh.2014.07.041.
56. M.J.Rosen, P.Minar, A.A.Vinks. Review article:applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094–1103. doi:10.1111/apt.13175.
57. J.F.Brandse, G.R.van den Brink, M.E.Wildenberg, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–5.e2. doi:10.1053/j.gastro.2015.04.016.• Clinical trial about dealing with the problem of primary nonresponse and accelerated clearance of anti-TNF.
58. S.Ben-Horin, U.Kopylov, Y.Chowers. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30. doi:10.1016/j.autrev.2013.06.002.
59. K.Papamichael, A.Gils, P.Rutgeerts, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD:evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182–197. doi:10.1097/MIB.0000000000000202.
60. E.J.Eshuis, W.A.Bemelman, A.A.van Bodegraven, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn’s disease:a randomized multicenter trial (LIR!C-trial). BMC Surg BioMed Central. 2008;8:15. doi:10.1186/1471-2482-8-15.
61. G.-T.Ho, L.Smith, S.Aitken, et al. The use of adalimumab in the management of refractory Crohn’s disease. Aliment Pharmacol Ther. 2008;27:308–315. doi:10.1111/j.1365-2036.2007.03583.x.
62. A.Swaminath, T.Ullman, M.Rosen, et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther. 2009;29:273–278. doi:10.1111/j.1365-2036.2008.03878.x.
63. M.Allez, S.Vermeire, N.Mozziconacci, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101. doi:10.1111/j.1365-2036.2009.04130.x.
64. R.Löfberg, E.V.Louis, W.Reinisch, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease:results from CARE. Inflamm Bowel Dis. 2012;18:1–9. doi:10.1002/ibd.21663.
65. K.Papamichael, O.Rivals, T.Billiet, et al. Long-term outcome of IBD patients with primary non-response to anti-TNF therapy. J Crohns Colitis. 2015;9:S– 58.
66. C.A.Siegel, G.Y.Melmed. Predicting response to anti-TNF agents for the treatment of crohn’s disease. Therap Adv Gastroenterol. 2009;2:245–251.
67. S.Ben-Horin, Y.Chowers. Review article:loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987–995. doi:10.1111/j.1365-2036.2011.04612.x.
68. F.Baert, M.Noman, S.Vermeire, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608. doi:10.1056/NEJMicm020037.
69. N.Vande Casteele, A.Gils, S.Singh, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962–971. doi:10.1038/ajg.2013.12.
70. B.Ungar, Y.Chowers, M.Yavzori, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–1264. doi:10.1136/gutjnl-2013-305259.
71. P.Rutgeerts, B.G.Feagan, G.R.Lichtenstein, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413. doi:10.1053/j.gastro.2003.11.014.• Landmark trial providing evidence for the use of infliximab scheduled rather than episodic treatment.
72. S.Vermeire, M.Noman, G.Van Assche, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–1231. doi:10.1136/gut.2006.099978.
73. J.Torres, R.K.Boyapati, N.A.Kennedy, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149:1716–1730. doi:10.1053/j.gastro.2015.08.055.
74. J.P.Gisbert, A.C.Marín, M.Chaparro. Systematic review:factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391–405. doi:10.1111/apt.13365.
75. G.Van Assche, C.Magdelaine-Beuzelin, G.D’Haens, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance:a randomized trial. Gastroenterology. 2008;134:1861–1868. doi:10.1053/j.gastro.2008.01.074.• Randomized controlled trial on the withdrawal of immunomodulation after 6 months of combination therapy in CD patients who are in stable remission.
76. A.Oussalah, J.-B.Chevaux, R.Fay, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol. 2010;105:1142–1149. doi:10.1038/ajg.2010.158.
77. D.Drobne, P.Bossuyt, C.Breynaert, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:514–21.e4. doi:10.1016/j.cgh.2014.07.027.• Retrospective analysis about de-escalation of therapy in CD patients on combination therapy by stopping the immunomodulator.
78. E.Louis, J.-Y.Mary, G.Vernier-Massouille, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.e5;quiz e31. doi:10.1053/j.gastro.2011.09.034.•• STORI trial:prospective trial evaluating IBD course after anti-TNF withdrawal in CD patients on combination therapy.
79. T.Molnár, P.L.Lakatos, K.Farkas, et al. Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther. 2013;37:225–233. doi:10.1111/apt.12160.
80. A.W.G.Waugh, S.Garg, K.Matic, et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab:long-term follow-up of a single centre cohort. Aliment Pharmacol Ther. 2010;32:1129–1134. doi:10.1111/j.1365-2036.2010.04446.x.
81. C.Steenholdt, A.Molazahi, M.A.Ainsworth, et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission:an observational Danish single center study. Scand J Gastroenterol. 2012;47:518–527. doi:10.3109/00365521.2012.660541.
82. S.Ben-Horin, Y.Chowers, B.Ungar, et al. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015;42:356–364. doi:10.1111/apt.13365.
83. J.P.Gisbert, A.C.Marín, M.Chaparro. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease:systematic review and meta-analysis. Am J Gastroenterol. 2016;111:632–647. doi:10.1038/ajg.2016.54.•• Meta-analysis about the risk of relapse after discontinuation of anti-TNF therapy in patients with IBD.
84. N.Vande Casteele, M.Ferrante, G.Van Assche, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–9.e3. doi:10.1053/j.gastro.2015.02.031.•• TAXIT trial:prospective randomized controlled trial evaluating the use of individualized dosing based on drug exposure in responder IBD patients treated with infliximab maintenance.
85. N.Williet, S.Paul, L.Peyrin-Biroulet, et al. Pharmacokinetics of infliximab and reduction of treatment for inflammatory bowel diseases. Dig Dis Sci. 2016;61:990–995. doi:10.1007/s10620-015-3984-2.
86. J.S.Kang, M.H.Lee. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1–10. doi:10.3904/kjim.2009.24.3.279.
87. C.Felice, M.Marzo, D.Pugliese, et al. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opin Biol Ther. 2015;15:1107–1117. doi:10.1517/14712598.2015.1044434.
88. C.Steenholdt, J.Brynskov, O.Ø.Thomsen, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment:a randomised, controlled trial. Gut. 2014;63:919–927. doi:10.1136/gutjnl-2013-305279.
89. G.D’haens, S.Vermeire, G.Lambrecht, et al. Drug-concentration versus symptom-driven dose adaptations of Infliximab in patients with active Crohn’s disease:a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis. 2016;10:S24.
90. W.Park, P.Hrycaj, S.Jeka, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis:the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. doi:10.1136/annrheumdis-2012-203091.• PLANETAS:prospective study proving similarity of infliximab biosimilar and infliximab originator in patients with ankylosing spondylitis.
91. D.H.Yoo, P.Hrycaj, P.Miranda, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. doi:10.1136/annrheumdis-2012-203090.• PLANETRA:prospective study proving similarity of infliximab biosimilar and infliximab originator in patients with rheumatoid arthritis.
92. V.Brodszky, P.Baji, O.Balogh, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65–71. doi:10.1007/s10198-014-0595-3.
93. S.Schreiber. An update on biosimilar drugs for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):1–3. doi:10.1586/17474124.2014.940897.
94. Y.-S.Kang, H.H.Moon, S.E.Lee, et al. Clinical experience of the use of CT-P13, a Biosimilar to infliximab in patients with inflammatory bowel disease:a case series. Dig Dis Sci. 2015;60:951–956. doi:10.1007/s10620-014-3392-z.
95. Y.S.Jung, D.ParkIl, Y.H.Kim, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease:a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–1712. doi:10.1111/jgh.12997.
96. K.B.Gecse, B.D.Lovász, K.Farkas, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases:a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10:133–140. doi:10.1093/ecco-jcc/jjv220.
97. S.Ben-Horin, M.Yavzori, I.Benhar, et al. Cross-immunogenicity:antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65:1132–1138.
98. M.Bettey, L.Downey, C.Underhill, et al. Outcomes of a managed switching programme changing IBD patients established or originator infliximab to biosimilar infliximab. J Crohns Colitis. 2016;10:S43–4.
99. L.Smits, L.Derikx, J.Drenth, et al. Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients:a prospective observational cohort study. J Crohns Colitis. 2016;10:S44–5. doi:10.1093/ecco-jcc/jjw019.059.
100. M.Kolar, D.Duricova, M.Brotlik, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (RemsimaTM) is effective and safe. J Crohns Colitis. 2016;10:S45–6.
101. B.Lovasz, Z.Kurti, M.Rutka, et al. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy:results from a prospective nationwide cohort. J Crohns Colitis. 2016;10:S46.
102. F.Salaffi, M.Carotti, M.Di Carlo, et al. Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J Clin Rheumatol. 2015;21:419–425. doi:10.1097/RHU.0000000000000320.
103. K.C.Bhol, D.E.Tracey, B.R.Lemos, et al. AVX-470:a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2273–2281. doi:10.1097/MIB.0b013e31828c8512.
104. M.S.Harris, D.Hartman, B.R.Lemos, et al. AVX-470, an orally delivered anti-TNF antibody for treatment of active ulcerative colitis:results of a first-in-human trial. J Crohns Colitis. 2016. Epub 2016 Jan28. doi:10.1093/ecco-jcc/jjw036.• First in-human trial with an oral anti-TNF agent in UC patients.
105. D.S.Hartman, D.E.Tracey, B.R.Lemos, et al. Effects of AVX-470, an oral, locally acting anti-tumour necrosis factor antibody, on tissue biomarkers in patients with active ulcerative colitis. J Crohns Colitis. 2016. Epub 2016 Jan22. doi:10.1093/ecco-jcc/jjw026.
106. L.Semerano, E.Assier, L.Delavallée, et al. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther. 2011;11:545–550. doi:10.1517/14712598.2011.566856.
107. P.Durez, P.Vandepapeliere, P.Miranda, et al. Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis:a phase II randomized, controlled clinical trial. PLoS One. 2014;9:e113465. doi:10.1371/journal.pone.0113465.
108. C.Abraham, J.H.Cho. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078. doi:10.1056/NEJMra0804647.
109. J.Gu, T.Ghayur. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Methods Enzymol. 2012;502:25–41.
110. S.E.Lacy, C.Wu, D.J.Ambrosi, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7:605–619. doi:10.1080/19420862.2015.1026501.
111. E.Louis, S.Vermeire, P.Rutgeerts, et al. A positive response to infliximab in Crohn disease:association with a higher systemic inflammation before treatment but not with −308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818–824.
112. W.Reinisch, Y.Wang, B.J.Oddens, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease:a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–576. doi:10.1111/j.1365-2036.2011.04987.x.
113. M.Jürgens, J.M.Mahachie John, I.Cleynen, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–7.e1. doi:10.1016/j.cgh.2011.02.008.
114. F.Magro, E.Rodrigues-Pinto, J.Santos-Antunes, et al. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129–136. doi:10.1016/j.crohns.2013.07.005.
115. T.H.J.Florin, E.W.J.Paterson, E.V.Fowler, et al. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306–311. doi:10.1080/00365520500217118.
116. T.Hibi, A.Sakuraba, M.Watanabe, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease. J Gastroenterol. 2014;49:254–262. doi:10.1007/s00535-013-0895-x.
117. M.Pierik, S.Vermeire, K.V.Steen, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther. 2004;20:303–310. doi:10.1111/j.1365-2036.2004.01946.x.
118. J.Oliver, D.Plant, A.P.Webster, et al. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomark Med. 2015;9:499–512. doi:10.2217/bmm.15.18.
119. Q.Tong, L.Zhao, X.-D.Qian, et al. Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease:a meta-analysis. Pharmacogenomics. 2013;14:1691–1700. doi:10.2217/pgs.13.146.
120. H.Matsukura, S.Ikeda, N.Yoshimura, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn’s disease. Aliment Pharmacol Ther. 2008;27:765–770. doi:10.1111/j.1365-2036.2008.03630.x.
121. L.M.Medrano, C.Taxonera, A.Márquez, et al. Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab. Hum Immunol. 2014;75:71–75. doi:10.1016/j.humimm.2014.05.004.
122. T.Billiet, I.Cleynen, M.Ferrante, et al. A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease. J Crohns Colitis. 2016;10:S3.
123. G.Toedter, K.Li, C.Marano, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011;106:1272–1280. doi:10.1038/ajg.2011.83.
124. I.Arijs, R.Quintens, L.Van Lommel, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn’s disease. Inflamm Bowel Dis. 2010;16:2090–2098. doi:10.1002/ibd.21253.
125. R.Atreya, H.Neumann, C.Neufert, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med. 2014;20:313–318. doi:10.1038/nm.3462.
126. S.R.Kapoor, A.Filer, M.A.Fitzpatrick, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448–1456. doi:10.1002/art.37921.• Clinical trial providing insight in predictive biomarkers for anti-TNF therapy in CD.
127. T.Billiet, K.Papamichael, M.De Bruyn, et al. A matrix-based model predicts primary response to infliximab in Crohn’s disease. J Crohns Colitis. 2015;9:1120–1126. doi:10.1093/ecco-jcc/jjv156.
128. B.Ungar, I.Levy, Y.Yavne, et al. Optimizing anti-TNF-α therapy:serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550–7.e2. doi:10.1016/j.cgh.2015.10.025.
129. S.Paul, E.Del Tedesco, H.Marotte, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease:a prospective study. Inflamm Bowel Dis. 2013;19:2568–2576. doi:10.1097/MIB.0b013e31828c8512.
130. N.Vande Casteele, A.Gils. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease:adding value to current practice. J Clin Pharmacol. 2015;55(Suppl 3):S39–50. doi:10.1016/j.cgh.2015.11.014.
131. S.Sharma, D.Eckert, J.S.Hyams, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease:results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21:783–792. doi:10.1097/MIB.0000000000000327.
132. F.Cornillie, S.B.Hanauer, R.H.Diamond, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab:a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721–1727. doi:10.1136/gutjnl-2012-304094.
133. K.Papamichael, T.Van Stappen, N.Vande Casteele, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;14:543–549. doi:10.1016/j.cgh.2015.11.014.
134. T.Kobayashi, Y.Suzuki, S.Motoya, et al. Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in ulcerative colitis. J Crohns Colitis. 2016;10:S24–5.
135. D.R.Mould, M.C.Dubinsky. Dashboard systems:pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55(Suppl 3):S51–9. doi:10.1002/jcph.370.
136. J.Lu, T.Van Stappen, D.Spasic, et al. Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients. Biosens Bioelectron. 2016;79:173–179. doi:10.1016/j.bios.2015.11.087.
137. The NOR-SWITCH study. (cited 2016 Mar14). Available from:https://clinicaltrials.gov/ct2/show/record/NCT02148640
138. N.N.Andersen, T.Jess. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20:16014–16019. doi:10.3748/wjg.v20.i43.16014.
139. G.R.Burmester, R.Panaccione, K.B.Gordon, et al. Adalimumab:long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524. doi:10.1136/annrheumdis-2011-201244.
140. U.Kopylov, M.Vutcovici, A.Kezouh, et al. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics:a Quebec claims database Study. Inflamm Bowel Dis. 2015;21:1847–1853. doi:10.1097/MIB.0000000000000457.
141. J.Askling, K.Fahrbach, B.Nordstrom, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors:meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119–130. doi:10.1002/pds.2046.
142. B.Nardone, J.A.Hammel, D.W.Raisch, et al. Melanoma associated with tumour necrosis factor-α inhibitors:a research on adverse drug events and reports (RADAR) project. Br J Dermatol. 2014;170:1170–1172. doi:10.1111/bjd.12779.
143. IBD Cancer and Serious infection in Europe (I-CARE). [cited 2016 Mar14]. Available from:https://clinicaltrials.gov/ct2/show/NCT02377258
144. E.Del Tedesco, S.Paul, H.Marotte, et al. Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy:a prospective study. J Crohns Colitis. 2016;10:S7.
145. Enhanced Algorithm for Crohn’s Treatment Incorporating Early Combination Therapy (REACT2). [cited 2016 Mar28]. Available from:https://clinicaltrials.gov/ct2/show/NCT01698307
146. Efficacy and safety of two treatment models in subjects with moderate-to-severe Crohn’s disease (CALM). [cited 2016 Mar12]. Available from:https://clinicaltrials.gov/ct2/show/study/NCT01235689